Immuneering Corporation (IMRX)
NASDAQ: IMRX · IEX Real-Time Price · USD
1.530
+0.110 (7.75%)
At close: May 1, 2024, 4:00 PM
1.630
+0.100 (6.54%)
After-hours: May 1, 2024, 7:59 PM EDT
Immuneering Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
68
Market Cap
45.37M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 316.95K | -1.76M | -84.76% |
| Dec 31, 2021 | 2.08M | -231.57K | -10.02% |
| Dec 31, 2020 | 2.31M | 391.83K | 20.41% |
| Dec 31, 2019 | 1.92M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rockwell Medical | 83.61M |
| IRIDEX | 51.87M |
| Cytosorbents | 36.35M |
| Daxor | 34.67M |
| Dyadic International | 2.90M |
| Lucid Diagnostics | 2.43M |
IMRX News
- 22 days ago - IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models - GlobeNewsWire
- 4 weeks ago - Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations - GlobeNewsWire
- 6 weeks ago - Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - GlobeNewsWire
- 7 weeks ago - Immuneering Appoints Thomas J. Schall, Ph.D. - GlobeNewsWire
- 7 weeks ago - Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors - GlobeNewsWire
- 2 months ago - Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning - Newsfile Corp
- 2 months ago - Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024 - GlobeNewsWire